Here we studied A-GO-mediated activation of FXN expression in FRDA patient-derived primary fibroblasts using locked nucleic acid/DNA (LNA/DNA) mixmers with a fully phosphorothioate (PS)-modified backbone targeting the H-DNA structure in the first intron of the FXN gene. This evidence concerns the gene FXN and Friedreich ataxia.